2024
Dominant, Lesional Post-Traumatic Temporal Lobe Epilepsy
Herlopian A. Dominant, Lesional Post-Traumatic Temporal Lobe Epilepsy. 2024, 135-160. DOI: 10.1007/978-3-031-23828-4_7.Peer-Reviewed Original ResearchTraumatic brain injuryImprove medication complianceIntracranial monitoringPatient populationExtent of cerebral injuryAnalysis of patientsNeuroimaging modalitiesPost-traumatic epilepsyMedication adherenceMedication compliancePredictors of outcomeBrain injuryStages of epileptogenesisSurgical outcomesIctal onsetResection surgerySurgical interventionTonic seizuresCerebral injuryHistopathological analysisPatientsVisual phenomenaEpilepsyOutcomesInjury
2020
Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer
Pusztai L, Taylor R, Mougalian SS. Text Messaging to Increase Compliance with Adjuvant Endocrine Therapy in Breast Cancer. Cancer Cell 2020, 38: 323-325. PMID: 32931742, DOI: 10.1016/j.ccell.2020.08.006.Peer-Reviewed Original Research
2018
Pharmacological and Behavioral Treatment of Opioid Use Disorder
Sofuoglu M, DeVito E, Carroll K. Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research And Clinical Practice 2018, 1: 4-15. PMCID: PMC9175946, DOI: 10.1176/appi.prcp.20180006.Peer-Reviewed Original ResearchOpioid use disorderMedication-Assisted TreatmentSubstance use conditionsBehavioral treatmentTreatment retentionUse disordersBehavioral interventionsOpioid withdrawal symptomsFirst-line treatmentMechanism of actionOUD treatmentComorbid conditionsMedication complianceWithdrawal symptomsClinical overviewClinical guidelinesOpioid receptorsAdrenergic agonistsNonsystematic reviewDrug AdministrationKey pharmacologicalBehavioral therapyTreatment effectivenessComplex needsTreatment
2016
Comparison of Intensive Case Management for Psychotic and Nonpsychotic Patients
Mohamed S. Comparison of Intensive Case Management for Psychotic and Nonpsychotic Patients. Psychological Services 2016, 13: 10-19. PMID: 26168139, DOI: 10.1037/ser0000041.Peer-Reviewed Original ResearchConceptsAssertive community treatmentPsychotic symptomsAnalysis of covariancePsychotic disordersIntensive case management programIntensive case management servicesSevere psychotic symptomsIntensive case managementCommunity-based careCase management programCase management servicesInpatient bed availabilityCommunity-based service programsBaseline characteristicsMedication complianceNonpsychotic patientsNonpsychotic disordersOutcome dataPsychotic diagnosesHospital useCommunity treatmentSuch symptomsBed availabilitySymptomsCase management
2014
Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia
Zhang J, Rosenheck R, Mohamed S, Zhou Y, Chang Q, Ning Y, He H. Association of symptom severity, insight and increased pharmacologic side effects in acutely hospitalized patients with schizophrenia. Comprehensive Psychiatry 2014, 55: 1914-1919. PMID: 25217308, DOI: 10.1016/j.comppsych.2014.07.018.Peer-Reviewed Original ResearchConceptsPharmacologic side effectsSevere side effectsGreater medication complianceHigher medication dosagesPANSS total scoreSevere symptomsSide effectsMedication complianceMedication dosageITAQ scoresHigh dosesTotal scorePoor treatment complianceSide effect scoresLarge psychiatric hospitalRelationship of symptomsNegative Syndrome ScaleTreatment Attitudes QuestionnaireStepwise multiple linear regression analysisInteraction of symptomsInsightful patientsTreatment emergentHospital dischargePrescribed medicationsTreatment complianceDifferences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia
Leatherman SM, Liang MH, Krystal JH, Lew RA, Valley D, Thwin SS, Rosenheck RA. Differences in Treatment Effect Among Clinical Subgroups in a Randomized Clinical Trial of Long-Acting Injectable Risperidone and Oral Antipsychotics in Unstable Chronic Schizophrenia. The Journal Of Nervous And Mental Disease 2014, 202: 13-17. PMID: 24375206, DOI: 10.1097/nmd.0000000000000069.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, OralAdultAgedAntipsychotic AgentsChronic DiseaseDrug Administration ScheduleFemaleHospitalizationHumansInjections, IntramuscularMaleMiddle AgedProportional Hazards ModelsPsychotic DisordersQuality of LifeRisk AssessmentRisperidoneSchizophreniaSchizophrenic PsychologySeverity of Illness IndexSubstance-Related DisordersTreatment OutcomeConceptsQuality of lifeOral antipsychoticsOral treatmentInjectable risperidoneCox regressionTreatment effectsLong-Acting Injectable RisperidoneBody mass indexPsychiatric service useSubstance abuse outcomesSubstance use outcomesLAI risperidonePrimary endpointStudy entryWhite patientsClinical outcomesMass indexUnstable patientsMedication compliancePsychiatric rehospitalizationChronic schizophreniaClinical trialsClinical subgroupsPsychiatric hospitalizationPsychiatric symptoms
2011
Implications of Weight-Based Stigma and Self-Bias on Quality of Life Among Individuals With Schizophrenia
Barber JA, Palmese L, Reutenauer EL, Grilo CM, Tek C. Implications of Weight-Based Stigma and Self-Bias on Quality of Life Among Individuals With Schizophrenia. The Journal Of Nervous And Mental Disease 2011, 199: 431-435. PMID: 21716053, PMCID: PMC3135000, DOI: 10.1097/nmd.0b013e318221403d.Peer-Reviewed Original ResearchConceptsQuality of lifeWeight-based stigmatizationNonpsychiatric samplesMedication complianceUnderwent assessmentConsecutive seriesObese individualsClinical studiesLife measuresSchizoaffective disorderObese sampleSignificant stigmaSchizophreniaWeight stigmaWeight biasWeight measuresNegative affectPoor qualitySame extentStigma
2008
Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia
Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, Lieberman JA. Cross-sectional and Longitudinal Relationships Between Insight and Attitudes Toward Medication and Clinical Outcomes in Chronic Schizophrenia. Schizophrenia Bulletin 2008, 35: 336-346. PMID: 18586692, PMCID: PMC2659303, DOI: 10.1093/schbul/sbn067.Peer-Reviewed Original ResearchConceptsPositive medication attitudesMedication attitudesSymptoms of schizophreniaSchizophrenia symptomsGreater medication complianceDrug Attitude InventoryRelationship of insightClinical Antipsychotic TrialsTreatment Attitudes QuestionnaireGreater patient understandingLevel of depressionMixed model regression analysisLower symptom levelsRecovery-oriented servicesClinical outcomesMedication adherenceMedication complianceChronic schizophreniaAntipsychotic TrialsPatient understandingModel regression analysisMedicationsCommunity functioningPsychosocial rehabilitationSymptoms
2006
Selective Serotonin Reuptake Inhibitors and Suicidality in Juveniles: Review of the Evidence and Implications for Clinical Practice
Rey JM, Martin A. Selective Serotonin Reuptake Inhibitors and Suicidality in Juveniles: Review of the Evidence and Implications for Clinical Practice. Child And Adolescent Psychiatric Clinics Of North America 2006, 15: 221-237. PMID: 16321732, DOI: 10.1016/j.chc.2005.08.012.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsClinical practiceCareful clinical monitoringPharmacologic treatmentMedication complianceManic switchingSevere depressionClinical monitoringSuicidal behaviorBehavioral activationSuicidalityPersonal sufferingDepressionInhibitorsEvidenceNontreatment
2005
Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram
Petrakis IL, Nich C, Ralevski E. Psychotic Spectrum Disorders and Alcohol Abuse: A Review of Pharmacotherapeutic Strategies and a Report on the Effectiveness of Naltrexone and Disulfiram. Schizophrenia Bulletin 2005, 32: 644-654. PMID: 16887890, PMCID: PMC2632271, DOI: 10.1093/schbul/sbl010.Peer-Reviewed Original ResearchConceptsPsychotic spectrum disordersPharmacotherapeutic strategiesSchizoaffective disorderBipolar disorderMental illnessAlcohol dependenceBetter alcohol use outcomesEffectiveness of naltrexoneIntensive psychosocial treatmentComorbid mental illnessUse of disulfiramAxis I DisordersSubstance use disordersSpectrum disorderActive medicationAlcohol use outcomesPharmacotherapeutic optionsSignificant morbidityMedication complianceClinical trialsI disordersPsychosocial treatmentsGeneral populationSpecific treatmentAlcohol abuseNaltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders
Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B, Group V. Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders. Biological Psychiatry 2005, 57: 1128-1137. PMID: 15866552, DOI: 10.1016/j.biopsych.2005.02.016.Peer-Reviewed Original ResearchConceptsPsychiatric disordersAlcohol dependenceVeterans Administration Outpatient ClinicAxis I psychiatric disordersComorbid psychiatric disordersUse of disulfiramTreatment of alcoholismEvent Monitoring SystemAlcohol-dependent individualsActive medicationAdverse eventsSecondary outcomesPrimary outcomeMedication complianceOutpatient clinicSignificant group differencesGGT levelsMedication studiesPsychiatric symptomsAlcohol consumptionNaltrexoneAlcohol cravingDrug AdministrationConsecutive weeksPlacebo
2004
Efficacy of Disulfiram and Cognitive Behavior Therapy in Cocaine-DependentOutpatients: A Randomized Placebo-Controlled Trial
Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ. Efficacy of Disulfiram and Cognitive Behavior Therapy in Cocaine-DependentOutpatients: A Randomized Placebo-Controlled Trial. JAMA Psychiatry 2004, 61: 264-272. PMID: 14993114, PMCID: PMC3675448, DOI: 10.1001/archpsyc.61.3.264.Peer-Reviewed Original ResearchConceptsCocaine useGeneral populationCocaine dependenceEfficacy of disulfiramUrine toxicology screenOutpatient substance abuse treatment programsBehavior therapyConcurrent alcohol useSubstance abuse treatment programsCurrent cocaine dependenceCognitive behavior therapyDisulfiram useRandomized PlaceboDisulfiram therapyMedication complianceToxicology screenIdentical capsulesEffective therapyPlaceboCocaine-dependent individualsSelf-reported frequencyPromising treatmentPlacebo conditionInterpersonal psychotherapyTherapy
2003
Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia
Petrakis IL, O’Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH, VA Naltrexone Study Collaboration Group. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology 2003, 172: 291-297. PMID: 14634716, DOI: 10.1007/s00213-003-1658-9.Peer-Reviewed Original ResearchConceptsFederal Drug AdministrationSide effectsDrinking daysAlcohol dependenceDouble-blind fashionEfficacy of naltrexoneAbnormal involuntary movementsComorbid alcohol dependenceHeavy drinking daysTreatment of alcoholismSymptoms of schizophreniaRelapse prevention strategiesNegative Symptom ScaleNaltrexone augmentationTime-line follow-back methodNeuroleptic medicationNeuroleptic treatmentEffective medicationsMedication complianceComorbid schizophreniaOutpatient studyWeekly therapyEffective pharmacotherapyConclusionsThese dataInvoluntary movementsMedication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes
Cramer J, Rosenheck R, Kirk G, Krol W, Krystal J, 425 F. Medication Compliance Feedback and Monitoring in a Clinical Trial: Predictors and Outcomes. Value In Health 2003, 6: 566-573. PMID: 14627063, DOI: 10.1046/j.1524-4733.2003.65269.x.Peer-Reviewed Original ResearchConceptsMedication complianceClinical trialsLong-term clinical trialsHigh medication complianceVA Cooperative StudyMonths of treatmentOverall compliance rateAlcohol-dependent patientsPredictors of complianceMedication event monitoringMeasures of complianceDaily naltrexonePlacebo groupMulticenter trialPoor complianceGood compliersTreatment groupsCompliance dataBetter outcomesDrinking daysNaltrexoneCompliance rateCooperative StudyDosesTrials
2001
Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia.
Diaz E, Levine HB, Sullivan MC, Sernyak MJ, Hawkins KA, Cramer JA, Woods SW. Use of the Medication Event Monitoring System to estimate medication compliance in patients with schizophrenia. Journal Of Psychiatry And Neuroscience 2001, 26: 325-9. PMID: 11590972, PMCID: PMC167186.Peer-Reviewed Original ResearchConceptsMedication Event Monitoring SystemEvent Monitoring SystemFirst monthMedication complianceSchizoaffective disorderCompliance rateTypical antipsychotic treatmentMean compliance ratePsychiatric inpatient hospitalHospital readmission dataElectronic monitoring devicesConsecutive patientsMedication regimensMonth 3Antipsychotic treatmentReadmission dataInpatient hospitalPatientsMEMS capsSchizophrenic disordersBottle openingHospitalSchizophreniaMonthsDisordersTargeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement
Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement. JAMA Psychiatry 2001, 58: 755-761. PMID: 11483141, PMCID: PMC3651594, DOI: 10.1001/archpsyc.58.8.755.Peer-Reviewed Original ResearchConceptsDrug-free urine specimensNaltrexone treatmentFamily counseling sessionsContingency managementOpioid dependenceTreatment retentionUrine specimensBehavioral therapyOpioid-dependent individualsCounseling sessionsDrug use outcomesSubstance abuse outcomesNaltrexone complianceNaltrexone therapyOpioid useAvailable pharmacotherapiesMedication complianceSpecific pharmacotherapySignificant improvementTherapyUse outcomesAbuse outcomesPrincipal outcomePharmacotherapyTreatment
2000
Thrice-weekly versus daily buprenorphine maintenance
Schottenfeld R, Pakes J, O’Connor P, Chawarski M, Oliveto A, Kosten T. Thrice-weekly versus daily buprenorphine maintenance. Biological Psychiatry 2000, 47: 1072-1079. PMID: 10862807, DOI: 10.1016/s0006-3223(99)00270-x.Peer-Reviewed Original ResearchConceptsSublingual buprenorphineMaintenance treatmentSelf-reported illicit drug useDrug useOpioid agonist maintenance treatmentOpioid-positive urine testsAgonist maintenance treatmentDaily clinic attendanceDaily sublingual buprenorphineThrice-weekly dosingOpioid-dependent patientsUrine toxicology testsSignificant differencesIllicit drug useSelf-reported numberBuprenorphine maintenanceClinic attendanceWeekly doseIllicit opioidsMedication complianceThrice weeklyUrine testsOutcome measuresBuprenorphineCounseling attendanceNaltrexone-Induced Nausea in Patients Treated for Alcohol Dependence: Clinical Predictors and Evidence for Opioid-Mediated Effects
O'Malley S, Krishnan-Sarin S, Farren C, O'Connor P. Naltrexone-Induced Nausea in Patients Treated for Alcohol Dependence: Clinical Predictors and Evidence for Opioid-Mediated Effects. Journal Of Clinical Psychopharmacology 2000, 20: 69-76. PMID: 10653211, DOI: 10.1097/00004714-200002000-00012.Peer-Reviewed Original ResearchConceptsRisk of nauseaEndogenous opioid systemIntensity of drinkingSevere nauseaOpioid systemAlcohol useLight drinkersMost alcoholic patientsWeeks of naltrexoneOpen-label trialLong-term alcohol usePoor medication compliancePretreatment patient characteristicsLogistic regression analysisAlcohol-dependent subjectsDays of abstinenceDuration of abstinenceSignificant nauseaPatient characteristicsClinical predictorsEndogenous opioidsMedication complianceAlcoholic patientsNaltrexone doseRisk factors
1999
Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications.
Namkoong K, Farren CK, O'Connor PG, O'Malley SS. Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications. The Journal Of Clinical Psychiatry 1999, 60: 449-53. PMID: 10453799, DOI: 10.4088/jcp.v60n0706.Peer-Reviewed Original ResearchConceptsMedication Event Monitoring SystemMedication compliancePill countAlcohol dependenceOpen-label studyPill-taking behaviorSample of patientsEvent Monitoring SystemMeasurement of complianceEstimates of complianceCompliant groupPharmacotherapy researchTreatment outcomesClinical utilityCompliance rateNaltrexoneClinical implicationsOverall outcomeDrinking outcomesPatientsMEMS dataOutcomesCountTreatmentComplianceQuality of care for patients hospitalized with heart failure at academic medical centers
Nohria A, Chen Y, Morton D, Walsh R, Vlasses P, Krumholz H. Quality of care for patients hospitalized with heart failure at academic medical centers. American Heart Journal 1999, 137: 1028-1034. PMID: 10347327, DOI: 10.1016/s0002-8703(99)70358-3.Peer-Reviewed Original ResearchConceptsLeft ventricular ejection fractionCongestive heart failureAcademic medical centerTime of dischargeStandard of careMedical CenterHeart failureACE inhibitorsAssessment of LVEFDiagnosis of CHFDaily weightEnzyme inhibitor therapyRetrospective chart reviewVentricular ejection fractionLarge clinical trialsPatient education guidelinesQuality of careHealth care policyChart reviewDietary counselingHospital dischargeEjection fractionInhibitor therapyTreatment guidelinesMedication compliance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply